Loading...
Sprouty2 loss‐induced IL6 drives castration‐resistant prostate cancer through scavenger receptor B1
Metastatic castration‐resistant prostate cancer (mCRPC) is a lethal form of treatment‐resistant prostate cancer and poses significant therapeutic challenges. Deregulated receptor tyrosine kinase (RTK) signalling mediated by loss of tumour suppressor Sprouty2 (SPRY2) is associated with treatment resi...
Na minha lista:
| Udgivet i: | EMBO Mol Med |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5887544/ https://ncbi.nlm.nih.gov/pubmed/29540470 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201708347 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|